RZLT Rezolute, Inc. Stock Quote

RZLT [NASD]

Index	-	P/E	-	EPS (ttm)	-2.72	Insider Own	44.84%	Shs Outstand	8.35M	Perf Week	0.00%
Market Cap	56.03M	Forward P/E	-	EPS next Y	-2.33	Insider Trans	-	Shs Float	4.75M	Perf Month	-14.56%
Income	-20.90M	PEG	-	EPS next Q	-0.90	Inst Own	31.30%	Short Float	0.62%	Perf Quarter	-41.44%
Sales	-	P/S	-	EPS this Y	22.90%	Inst Trans	14.42%	Short Ratio	0.49	Perf Half Y	-0.46%
Book/sh	3.13	P/B	2.08	EPS next Y	-38.30%	ROA	-68.60%	Target Price	25.40	Perf Year	-71.11%
Cash/sh	4.76	P/C	1.37	EPS next 5Y	-	ROE	-87.50%	52W Range	5.86 - 23.50	Perf YTD	-45.79%
Dividend	-	P/FCF	-	EPS past 5Y	42.20%	ROI	-	52W High	-72.60%	Beta	3.64
Dividend %	-	Quick Ratio	21.30	Sales past 5Y	-	Gross Margin	-	52W Low	9.90%	ATR	0.44
Employees	26	Current Ratio	21.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	29.04	Volatility	4.38% 5.71%
Optionable	No	Debt/Eq	0.54	EPS Q/Q	-28.10%	Profit Margin	-	Rel Volume	0.58	Prev Close	6.50
Shortable	Yes	LT Debt/Eq	0.54	Earnings	-	Payout	-	Avg Volume	59.67K	Price	6.44
Recom	1.60	SMA20	-7.02%	SMA50	-22.02%	SMA200	-34.58%	Volume	26,833	Change	-0.92%

Sep-08-21

Initiated

ROTH Capital

Buy

$21

May-27-21

Initiated

Oppenheimer

Outperform

$25

May-25-21

Initiated

H.C. Wainwright

Buy

$21

Oct-19-21 12:14PM	Do Institutions Own Rezolute, Inc. (NASDAQ:RZLT) Shares? Simply Wall St.
Oct-13-21 08:10AM	Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering GlobeNewswire -14.19%
Oct-12-21 04:05PM	Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering GlobeNewswire
Sep-22-21 04:05PM	Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021 GlobeNewswire
Sep-15-21 04:56PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress GlobeNewswire
Sep-09-21 04:05PM	Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism GlobeNewswire
Sep-07-21 04:05PM	Rezolute to Participate in Upcoming Virtual Healthcare Conferences GlobeNewswire +5.41%
Aug-10-21 07:00AM	Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolutes Oral PKI for Treatment of DME GlobeNewswire +6.37%
Aug-03-21 07:00AM	Rezolute to Participate in Upcoming Virtual Healthcare Conferences GlobeNewswire
Jun-28-21 07:00AM	Rezolute Added to Russell Microcap® Index GlobeNewswire
Jun-24-21 09:01PM	Oppenheimer Bets on These 2 Stocks; Sees at Least 80% Upside Ahead TipRanks
Jun-03-21 05:35AM	Will Rezolute (NASDAQ:RZLT) Spend Its Cash Wisely? Simply Wall St.
May-31-21 10:17AM	3 Strong Buy Stocks with 100% Upside Potential TipRanks
May-27-21 07:00AM	Rezolute to Participate in Upcoming Virtual Healthcare Conferences GlobeNewswire +40.31%
May-20-21 07:00AM	Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs GlobeNewswire
May-18-21 07:00AM	Rezolute Appoints Leading Ophthalmology Expert, Quan Dong Nguyen, MD, MSc, FAAO, FARVO, to Scientific Advisory Board GlobeNewswire
May-17-21 04:05PM	Rezolute Reports Third Quarter Fiscal 2021 Financial Results and Highlights Recent Company Progress GlobeNewswire
07:00AM	Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit GlobeNewswire
May-04-21 08:00AM	Rezolute Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema GlobeNewswire
Apr-19-21 08:00AM	Rezolute Announces $30 Million Debt Financing Agreement with SLR Capital Partners GlobeNewswire
Mar-22-21 08:00AM	Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021 GlobeNewswire
Mar-08-21 08:00AM	Rezolute Strengthens Board of Directors with Key Appointments of Leading Rare Disease Experts GlobeNewswire +24.96%
Mar-02-21 05:16PM	Rezolute to Participate in Upcoming Investor Conferences in March GlobeNewswire -5.34%
Feb-10-21 04:05PM	Rezolute Reports Second Quarter Fiscal 2021 Financial Results GlobeNewswire -9.07%
Jan-12-21 08:30AM	Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema GlobeNewswire +6.84%
Jan-11-21 07:56AM	What Is The Ownership Structure Like For Rezolute, Inc. (NASDAQ:RZLT)? Simply Wall St. -6.15%
Dec-28-20 04:05PM	Rezolute Announces Change of Transfer Agent GlobeNewswire
Dec-03-20 08:00AM	FDA Clears Rezolutes IND Application for RZ402 GlobeNewswire +7.64%
Nov-19-20 08:00AM	Rezolute to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference GlobeNewswire
Nov-05-20 08:00AM	Rezolute Announces Uplisting to the Nasdaq Capital Market GlobeNewswire +11.11%
Oct-09-20 08:30AM	Rezolute Announces $41 Million Private Placement with Leading Investment Firms and Prepares to Imminently Up-list to Nasdaq GlobeNewswire +8.75%
Sep-10-20 08:00AM	Rezolute, Inc. Welcomes Pharmaceutical Industry Leader Philippe Fauchet to its Board of Directors GlobeNewswire
Jul-27-20 08:00AM	Rezolute, Inc. Provides Updates in the Context of the COVID-19 Pandemic: Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism GlobeNewswire
Jun-15-20 08:30AM	Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science GlobeNewswire -10.58%
May-28-20 08:30AM	Rezolute to Present Clinical Data for RZ358, Lead Candidate in Phase 2b Trial in Congenital Hyperinsulinism at Virtual Pediatric Endocrine Society 2020 Annual Meeting GlobeNewswire

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience